|
|
||
| |
Venture capital firms and funds in Europe 128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Venture Capital Terms and Topics
-
Clarus Ventures Leads $32 Million in Series C Funding Round for TetraLogic Pharmaceuticals
August 11th, 2010 1 comment
Based in Malvern, Pennsylvania, TetraLogic Pharmaceuticals has announced on August 10, 2010, that it has completed a $32 million investment in series C funding round, led by Clarus Ventures. Other investors who participated in this funding round include the company’s existing investors, who are Amgen Ventures, Healthcare Ventures, Lattarell Venture Partners, Novitas Capital, Quaker BioVentures, and the Vertical Group. A second new investor, Hatteras Venture Partners also participated in this funding round.
TetraLogic Pharmaceuticals is a private company in the biopharmaceuticals industry which discovers and develops small molecular drugs that program the death pathways of cells to treat debilitating disease, such as different varieties of cancer and other debilitating disorders, such as autoimmune diseases and inflammatory diseases. Currently, the company is working of the SMAC series of molecular drugs to treat cancer and the above mentioned disorders.
Proceeds from this latest round of funding will go to fund the company’s latest study and development of the TL32711 drug that is to be clinically developed for the treatment of cancer. TL32711 is a SMAC mimetic that neutralizes the inhibitors which inhibit the cell death of cancerous tumor cells. To present, the TL32711 is undergoing Phase 1 in clinical studies and the researchers at TL32711 are currently studying the possibility that this drug can be used as a single agent on cancer patients who have solid tumors. Researchers are also looking into the possibility that TL32711 can also be used together with other treatments for lymphoma patients. TetraLogic plans in the near future to complete Phase 1a and 1b of clinical studies of TL32711 and to begin Phase 2a of clinical studies.
According to the managing director of Clarus Ventures, Dr. Michael Steinmetz, PhD., SMAC technology shows great promise in the treatment of cancer and has the potential to treat both solid and hematological cancers, which otherwise are usually resistant to other conventional therapies around to treat them. Dr. Steinmetz further added that the team at Clarus Ventures are encouraged in the results of the current research that TetraLogic has already done on TL32711. The possibility that this drug can fulfill a largely unmet need in treating some of the more difficult cancers.
TetraLogic’s CEO and president, John Gill, the fact that so many investors have shown interest and placed their money into the TL32711 is more proof that the enthusiasm that the team at TetraLogic has in this novel drug in the treatment of a wide variety of cancers. As a result of this recent funding round, the company now has the resources needed to complete Phase 1a of clinical studies and begin Phase 1b and even Phase 2a.
Clarus Ventures is a venture capital firm that has a vision in creating the healthcare products of the future. The firm was founded by a group of investment professionals who have extensive backgrounds in the healthcare and life sciences industries. Clarus currently has 1.2 billion in two funds dedicated to life sciences companies and its headquarters are based in Cambridge, Massachusetts with offices in Boston, Massachusetts and in San Francisco, California. Some other companies in Clarus’s portfolio include Achillion, Aerovance, Avanir, Biovex Therapeutics, Globus Medical, Link Medicine, and others.
1 responses to “Clarus Ventures Leads $32 Million in Series C Funding Round for TetraLogic Pharmaceuticals” 
Leave a reply
Latest Headlines:
Friday August 31, 2012
Zscaler Secures $38 Million Investment Round
Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.
Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects
Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding
Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies
Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains
Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster
Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility
Hi,
Good article and very nice site. I was wondering if anyone could help me find a healthcare investor, I know this is not a forum, but I have tried all possible channels and I have not found any contact details for any Seattle healthcare investors. Thank you in advance.